Nuvalent, Inc.

Oncology is, by far, the most lucrative market within biopharma, with Evaluate 2030 sales predictions of more than twice that of the next therapeutic area. In this contested and increasingly granular

Oncology is, by far, the most lucrative market within biopharma, with Evaluate 2030 sales predictions of more than twice that of the next therapeutic area. In this contested and increasingly granular

Biopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more. The follow-on public offering (FOPO) category made up the made up most (34%) of t

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from